All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the European Hematology Association (EHA) 2023 Hybrid Congress, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked: What were your highlights from EHA 2023?
What were your highlights from EHA 2023?
Roboz begins by summarizing the application of targeted agents to traditional chemotherapy regimens, and how the use of the FLT3 inhibitor midostaurin in the RATIFY trial has paved the way in changing the treatment landscape. Roboz goes on to review the use of gilteritinib in the MORPHO trial, which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD (internal tandem duplication)–positive acute myeloid leukemia (AML). Roboz also touches on how patients who are measurable residual disease (MRD)-positive have been responding to gilteritinib and the importance of MRD monitoring in patients with FLT3 mutations. Roboz then highlights the need to target the NPM1 mutation in patients with AML, based on late-breaking data gathered from the KOMET-001 trial, where patients with NPM1-mutant relapsed or refractory acute AML have been treated with the Menin inhibitor ziftomenib. Roboz rounds off by mentioning the importance of combining ziftomenib with current upfront therapies to try and prevent relapsed AML.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox